Page last updated: 2024-11-04

methyl methanesulfonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4156
CHEMBL ID313493
CHEBI ID25255
SCHEMBL ID63290
MeSH IDM0013613

Synonyms (97)

Synonym
CHEMBL313493
nsc-50256
nsc50256
methyl mesylate
as-dimethyl sulphite
wln: ws1&o1
methanesulfonic acid methyl ester
cb 1540
methylmethanesulfonate
methyl methansulfonate
methylmethane sulfonate
methylmethansulfonat
fda 0092
MMS ,
methyl ester of methanesulfonic acid
NCI60_004210
SPECTRUM_001850
cb1540
CHEBI:25255 ,
BSPBIO_002751
methanesulfonic acid, methyl ester
66-27-3
methyl methanesulfonate ,
inchi=1/c2h6o3s/c1-5-6(2,3)4/h1-2h
ccris 396
methanesulfonic acid, methyl ester (6ci,7ci,8ci,9ci)
methylsulfonic acid methyl ester
ai3-50052
as-dimethyl sulfite
hsdb 5103
NCGC00090697-01
einecs 200-625-0
c2h6o3s
methyl methanesulfonic acid
methylester kyseliny methansulfonove [czech]
methyl methanesulphonate
brn 1098586
methyl methansulphonate
methanesulphonic acid methyl ester
methylmethansulfonat [german]
methyl ester of methanesulphonic acid
dimethylsulfonate
methylmethanesulphonate
methyl methanesulfonate, 99%
NCGC00090697-02
NCGC00090697-03
KBIOGR_001192
KBIO2_004930
KBIO3_002251
KBIO2_002362
KBIOSS_002365
KBIO2_007498
SPECTRUM2_000917
SPBIO_000794
SPECTRUM4_000776
SPECTRUM3_001166
SPECTRUM330003
SPECTRUM5_001652
NCGC00090697-04
methyl methane sulfonate
methylmethansulphonate
methylmesylate
M0369
NCGC00090697-06
NCGC00090697-05
4-04-00-00011 (beilstein handbook reference)
at5c31j09g ,
methylester kyseliny methansulfonove
unii-at5c31j09g
C19181
tox21_202094
dtxsid7020845 ,
dtxcid10845
NCGC00259643-01
tox21_300299
NCGC00253916-01
cas-66-27-3
CCG-39749
FT-0628902
AKOS015900695
methyl methanesulfonate [iarc]
methyl methanesulfonate [mi]
methyl methanesulfonate [hsdb]
SCHEMBL63290
W-104766
methyl methanesulfonate, certified reference material, tracecert(r)
CS-W004702
mfcd00007557
Q3077242
AS-10021
methanesulfonate methyl
BCP34358
methyl-d3 methanesulfonate
EN300-1238092
SY012929
Z133684226
HY-W004702

Research Excerpts

Overview

Methyl methanesulfonate (MMS) is an alkylating agent that acts on DNA by preferentially methylating guanine and adenine bases. It is an extraordinarily poor mutagen compared to ethylnitrosourea (ENU) or even X-rays.

ExcerptReferenceRelevance
"Methyl methanesulfonate (MMS) is a highly toxic DNA-alkylating agent that has a potential to damage the structural integrity of DNA. "( Biophysical characterization of structural and conformational changes in methylmethane sulfonate modified DNA leading to the frizzled backbone structure and strand breaks in DNA.
Abidi, M; Ali, A; Habib, S; Kausar, T; Mir, AR; Mustafa, M; Nayeem, SM; Siddiqui, SA, 2022
)
2.16
"Methyl methanesulfonate (MMS) is an alkylating agent that acts on DNA by preferentially methylating guanine and adenine bases."( The Alkylating Agent Methyl Methanesulfonate Triggers Lipid Alterations at the Inner Nuclear Membrane That Are Independent from Its DNA-Damaging Ability.
Moriel-Carretero, M; Ovejero, S; Soulet, C, 2021
)
1.66
"Methyl methanesulfonate (MMS) is an alkylating agent commonly used in models of genotoxic stress. "( [RPN4 the yeast transcription factor promotes the complex defence against methyi, methanesulfonate].
Karpov, DS; Karpov, VL; Mironov, AS; Spasskaia, DS,
)
1.57
"Methyl methanesulfonate (MMS) is an alkylating agent that can induce cell death through apoptosis and necroptosis. "( Methyl methanesulfonate induces necroptosis in human lung adenoma A549 cells through the PIG-3-reactive oxygen species pathway.
Chi, L; Gao, X; Jiang, Y; Li, H; Shan, S; Yang, J; Zhang, G; Zhu, X, 2016
)
3.32
"Methyl methanesulfonate (MMS) is an extraordinarily poor mutagen compared to ethylnitrosourea (ENU) or even X-rays. "( Mutagenicity of methyl methanesulfonate (MMS) in vivo at the Dlb-1 native locus and a lacI transgene.
Heddle, JA; Tao, KS; Urlando, C, 1993
)
2.07
"Methyl methanesulfonate (MMS) is an SN2 type alkylating agent which predominantly methylates nitrogen atoms in purines. "( The role of mutation frequency decline and SOS repair systems in methyl methanesulfonate mutagenesis.
Grzesiuk, E, 1998
)
1.98
"Methyl methanesulfonate (MMS) is a direct acting methylating agent which produces apurinic sites that are transformed into DNA single-strand breaks by base excision repair. "( Detection of DNA primary damage by premature chromosome condensation in human peripheral blood lymphocytes treated with methyl methanesulfonate.
Carloni, M; de la Peña, NP; Fonti, E; Garcia, CL; Palitti, F, 2001
)
1.96

Effects

ExcerptReferenceRelevance
"Methyl methanesulfonate (MMS) has been shown to induce apoptosis in various cell types through p53-dependent pathways. "( Methyl methanesulfonate induces apoptosis in p53-deficient H1299 and Hep3B cells through a caspase 2- and mitochondria-associated pathway.
Duerksen-Hughes, P; Jiang, Y; Sun, L; Yang, J; Zhang, GL; Zhang, XY; Zhu, XQ, 2012
)
3.26

Treatment

Methyl methanesulfonate (MMS) treatment also activates checkpoints, inducing Rad53 phosphorylation in S phase. Treatment did not lead to the inactivation of nuclear photoreactivating enzyme after 24 h in the dark.

ExcerptReferenceRelevance
"Methyl methanesulfonate (MMS) treatment also activates checkpoints, inducing Rad53 phosphorylation in S phase."( The ATM-related Tel1 protein of Saccharomyces cerevisiae controls a checkpoint response following phleomycin treatment.
Matsumoto, K; Nakada, D; Shimomura, T; Sugimoto, K, 2003
)
1.04
"Treatment with methyl methanesulfonate to give a similar survival as the fluence of ultraviolet light did not lead to the inactivation of nuclear photoreactivating enzyme after 24 h in the dark."( Loss of nuclear photoreactivating enzyme following ultraviolet irradiation of Chlamydomonas.
Small, GD, 1980
)
0.6

Toxicity

ExcerptReferenceRelevance
" The toxic effects were determined by viscometry of alkaline cell lysates, nucleoid sedimentation, scheduled (SDS) and unscheduled (UDS) DNA synthesis and/or RNA synthesis."( A short-term test for nucleotoxicity that uses chick embryo cells treated in vitro and in vivo--physico-chemical and biochemical investigations.
Ignatius, A; Stammberger, I; Tempel, KH, 1992
)
0.28
" Delays in the transit through S-phase were evident 4 hours after exposure to toxic concentrations of either carcinogen and by 8 to 12 hours post-exposure at the lower concentrations."( Flow cytometric evaluation of cell-cycle progression in ethyl methanesulfonate and methyl methanesulfonate-exposed P3 cells: relationship to the induction of sister-chromatid exchanges and cellular toxicity.
Casciano, DA; Domon, OE; Kodell, RL; McGarrity, LJ; Morris, SM, 1991
)
0.51
" Qualitatively, the patterns of embryo malformations reported in treated embryos paralleled those observed in in vivo studies, especially in regard to adverse effects on central nervous system and craniofacial systems."( In vitro developmental toxicity of five direct-acting alkylating agents in rodent embryos: structure-activity patterns.
Faustman, EM; Gage, D; Kirby, Z; Varnum, M, 1989
)
0.28
" In comparison with control cells that were transfected with the parent vector, the ATase-expressing clones were considerably more resistant to the toxic effects of the methylating agents N-methyl-N-nitrosourea and methylmethanesulphonate or the chloroethylating agents Mz or taurine chloroethylnitrosourea, but unchanged in their susceptibility to the bis-chloroethylating agent nitrogen mustard."( Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents.
Dexter, TM; Jelinek, J; Kleibl, K; Margison, GP, 1988
)
0.27
"Pretreatment of H4 (rat hepatoma) cells for 48 hr with low nontoxic doses of alkylating agents [methyl methanesulfonate (MMS), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), and N-methyl-N-nitrosourea] renders the cells more resistant to the toxic effect of these compounds."( Adaptive response in mammalian cells: crossreactivity of different pretreatments on cytotoxicity as contrasted to mutagenicity.
Laval, F; Laval, J, 1984
)
0.49
" MNNG is about 100-fold more toxic than MMS on a molar basis."( Cytotoxicity of monofunctional alkylating agents. Methyl methanesulfonate and methyl-N'-nitro-N-nitrosoguanidine have different mechanisms of toxicity for 10T1/2 cells.
Grisham, JW; Smith, GJ, 1983
)
0.52
" It was concluded that a treatment period of 2 weeks is sufficient to allow evaluation of toxic effects of MMS on the male reproductive organs."( Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 15). Two-week and 4-week administration study of methyl methanesulfonate (MMS).
Kitamura, T; Kobayashi, K; Kuriyama, K; Ozawa, S; Shibata, N; Yokoi, R, 2000
)
0.51
" The most toxic MVOC was 1-decanol which was as effective as MMS in all test systems."( On the cytotoxicity of some microbial volatile organic compounds as studied in the human lung cell line A549.
Kreja, L; Seidel, HJ, 2002
)
0.31
" We recently showed the antioxidant effect of DPDS in V79 cells, and established the beneficial and toxic doses of this compound in this cell line."( Antioxidant activity of diphenyl diselenide prevents the genotoxicity of several mutagens in Chinese hamster V79 cells.
Moura, DJ; Pêgas Henriques, JA; Romano E Silva, AC; Rosa, RM; Saffi, J, 2007
)
0.34
" It is obvious that hawthorn, particularly flavonoids constituents with antioxidative activity, reduced the oxidative stress and genotoxicity induced by toxic compounds."( Protective effect of hawthorn extract against genotoxicity induced by methyl methanesulfonate in human lymphocytes.
Azadbakht, M; Hosseinimehr, SJ; Mahmodzadeh, A; Mohammadifar, S; Tanha, M, 2011
)
0.6
"There is still controversy whether adverse effects by genotoxic anthropogenic pollutants are linked to the decline of fish populations."( Reproductive and genotoxic effects in zebrafish after chronic exposure to methyl methanesulfonate in a multigeneration study.
Braunbeck, T; Faßbender, C, 2013
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"A modified assay for the detection of DNA single-strand breaks (SSBs) in human mononucleated white blood cells (MWBCs) based on the nick translation (NT) reaction was developed and combined with the test for unscheduled DNA synthesis (UDS)."( A novel technique for the detection of DNA single-strand breaks in human white blood cells and its combination with the unscheduled DNA synthesis assay.
Baumgartner, E; Einhaus, M; Holz, O; Krause, T; Meissner, R; Rüdiger, HW, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
"8 GHz microwave (MW) specific absorption rate (SAR, 3 W/kg) on human lymphocytes DNA damage induced by 4 chemical mutagens [mitomycin C (MMC), bleomycin (BLM), methyl methanesulfonate (MMS), and 4-nitroquinoline 1-oxide (4NQO)]."( [Influence of 1.8 GHz microwave on DNA damage induced by 4 chemical mutagens].
Deng, HP; He, JL; Jin, LF; Li, QY; Lou, JL; Lu, DQ; Wang, BH; Zheng, W, 2005
)
0.53
" First, we evaluated the responses of human cells to microwave exposure at a specific absorption rate (SAR) of 80 mW/kg, which corresponds to the limit of the average whole body SAR for general public exposure defined as a basic restriction in the International Commission on Non-Ionizing Radiation Protection (ICNIRP) guidelines."( DNA strand breaks are not induced in human cells exposed to 2.1425 GHz band CW and W-CDMA modulated radiofrequency fields allocated to mobile radio base stations.
Hirose, H; Komatsubara, Y; Miyakoshi, J; Nojima, T; Sakuma, N; Sekijima, M; Takeda, H, 2006
)
0.33

Dosage Studied

The nature of the dose-response relationship for various in vivo endpoints of exposure and effect were investigated. Methyl methanesulfonate (MMS) (10 microliters) was applied to the anal lips of day-old chicks to study mutagen targeting to DNA of dividing B-lymphocytes in the bursa.

ExcerptRelevanceReference
" With the methylating agents an early stimulation of DNA synthesis was observed, but this was depressed below the control levels at later times and with higher doses; hormone administration also resulted in a depression of DNA synthesis but, without any initial stimulation at the dosage employed."( The effect of hormone induced stress upon the extent of alkylation of rat liver nucleic acids by N-methyl-N-nitrosourea.
Craig, AW; Magin, MN; Margison, GP; O'Connor, PJ, 1975
)
0.25
" With a wild-type strain a whole dose-response curve was obtained."( Caffeine toxicity in drosophila strains having different MMS sensitivities.
Graf, U; Nigsch, J; Würgler, FE, 1977
)
0.26
" Parallel studies with HeLa cells showed a similar dose-response relationship between mutagen action and immunoreactivity."( Mutagen-induced disturbances in the DNA of human lymphocytes detected by antinucleoside antibodies.
Bases, R; Elequin, F; Kadish, A; Liebeskind, D; Mendez, F; Rubinstein, A; Wittner, D, 1979
)
0.26
"Male CD1 mice were dosed by intraperitoneal injection of 20, 40 or 80 mg of methyl methanesulphonate (MMS) per kg body weight or with the solvent, water."( Dominant lethal assays in male mice: evaluation of experimental design, statistical methods and the sensitivity of Charles River (CD1) mice.
Dean, BJ; Johnstone, A, 1977
)
0.26
" It was determined that rpr gene dosage was not a factor in recA complementation."( Serratia marcescens rpr gene sensitizes Escherichia coli wild-type, xth, and nfo strains to methyl methanesulphonate.
Braymer, HD; Murphy, KE, 1990
)
0.28
" A dose-response relationship was not observed in sperm morphology changes."( Induction of sperm abnormalities in mice by norfloxacin.
Maura, A; Pino, A, 1991
)
0.28
" The test relies on a gene dosage selection system in which hyperploidy is detected by the simultaneous increase in copy number of two alleles residing on the right arm of chromosome VIII: arg4-8 and cup1S (Rockmill and Fogel."( The detection of mitotic and meiotic chromosome gain in the yeast Saccharomyces cerevisiae: effects of methyl benzimidazol-2-yl carbamate, methyl methanesulfonate, ethyl methanesulfonate, dimethyl sulfoxide, propionitrile and cyclophosphamide monohydrate.
Fogel, S; Maloney, DH; Moser, SF; Piegorsch, WW; Resnick, MA; Whittaker, SG, 1990
)
0.48
" The UV dose-response curve of mus-26 showed a characteristic plateau in the range of 100-200 J/m2."( Epistasis, photoreactivation and mutagen sensitivity of DNA repair mutants upr-1 and mus-26 in Neurospora crassa.
Inoue, H; Ishii, C, 1989
)
0.28
" Two different slopes were observed in the dose-response curve when testing MMS with strain TA100."( Methyl methanesulphonate (MMS) is clearly mutagenic in S. typhimurium strain TA1535; a comparison with strain TA100.
Deininger, C; Eder, E; Wiedenmann, M, 1989
)
0.28
" Exposure of both cell types to MMS (0-20 mM) resulted in a linear dose-response relationship for the formation of DNA alkali-labile sites (i."( Methylmethanesulfonate-induced DNA damage and its repair in cultured human fibroblasts: normal rates of induction and removal of alkali-labile sites in xeroderma pigmentosum (group A) cells.
Liuzzi, M; Mirzayans, R; Paterson, MC, 1988
)
0.27
" Methyl methanesulfonate (MMS) (10 microliters) was applied to the anal lips of day-old chicks to study dose-response kinetics for mutagen targeting to DNA of dividing B-lymphocytes in the bursa."( Targeting of chemical mutagens to differentiating B-lymphocytes in vivo: detection by direct DNA labeling and sister chromatid exchange induction.
Bloom, SE; Dietert, RR; Nanna, UC, 1987
)
1.18
" Dose-response experiments, which included 10 dose levels, were performed, the data analyzed by linear regression, and the slope of the regression line (term: G0) used as a measure of DNA repair synthesis."( DNA repair synthesis in fibroblast strains from patients with actinic keratosis, squamous cell carcinoma, basal cell carcinoma, or malignant melanoma after treatment with ultraviolet light, N-acetoxy-2-acetyl-aminofluorene, methyl methanesulfonate, and N-
Burkhardt, MR; Edler, L; Jung, EG; Thielmann, HW, 1987
)
0.46
" MMS and ENU both showed shouldered dose-response curves for exponentially growing asynchronous cells, and the same cell-cycle pattern for synchronous cultures with cells in early S phase being the most sensitive."( Cell killing by various monofunctional alkylating agents in Chinese hamster ovary cells.
Goth-Goldstein, R; Hughes, M, 1987
)
0.27
" With a MMTS dosage of 133."( Blockade of acetylcholine synthesis in organophosphate poisoning.
Hopff, WH; Riggio, G; Waser, PG, 1984
)
0.27
" Intrauterine growth retardation, without an increase in gross abnormalities, was also observed in the offspring of pregnant New Zealand White rabbits dosed during the preimplantation stages of pregnancy with an "environmental cocktail" composed of ethanol, nicotine, caffeine, sodium salicylate, and dichloro-diphenyl-trichloro-ethane (DDT)."( Chemical exposure of embryos during the preimplantation stages of pregnancy: mortality rate and intrauterine development.
Dames, NM; Fabro, S; McLachlan, JA, 1984
)
0.27
" The presence of HU during chemical treatment and throughout this 18 h of incubation with [3H]dThd did not influence the dose-response curves obtained with UV, MMS, NA-AAF and BaP but it increased the input dose of MNNG, MMC, DMN and AFB1 required to give peak repair incorporation."( Chemical carcinogen induction of DNA-repair synthesis in human peripheral blood monocytes.
Igel, HJ; Kropko, ML; Lake, RS; McLachlan, S; Pezzutti, MR; Shoemaker, RH, 1980
)
0.26
" The time of expression and dose-response relationships obtained with gamma-radiation, methyl methanesulphonate, procarbazine, mitomycin C and benzo[a]pyrene are analysed in terms of this model."( Short-term tests for transplacentally active carcinogens. I. Micronucleus formation in fetal and maternal mouse erythroblasts.
Arlett, CF; Cole, J; Cole, RJ; Taylor, N, 1981
)
0.26
" A linear dose-response curve was observed for methyl methanesulfonate over a 100-fold dose range."( Methylation of cysteine in hemoglobin following exposure to methylating agents.
Bailey, E; Connors, TA; Farmer, PB; Gorf, SM; Rickard, J, 1981
)
0.52
"The shape of the dose-response curve for mutations induced at low doses of mutagenic agents in mammalian cells was studied."( Relationship between chemical damage of DNA and mutations in mammalian cells. I. Dose-response curves for the induction of 6-thioguanine-resistant mutants by low doses of monofunctional alkylating agents, X-rays and UV radiation in V79 Chinese hamster cel
Jenssen, D; Ramel, C, 1980
)
0.26
" The effects of animal age, differences in strain and dosing regimen, and length of expression time were evaluated."( Induction of hepatic mutations in lacI transgenic mice.
Hamner, RT; MacGregor, JT; Matthews, CD; Mirsalis, JC; O'Loughlin, KG; Provost, GS; Schindler, JE; Short, JM, 1993
)
0.29
" Under experimental conditions for quantitative DNA adsorption, a dose-response relationship between the extent of DNA modification and the repair synthesis activity was found."( A chemiluminescent microplate assay to detect DNA damage induced by genotoxic treatments.
Calsou, P; Fournié, GJ; Gosset, I; Hennebelle, I; Provot, C; Salles, B, 1995
)
0.29
" However, for MMS and UV light, which was included in this study for comparison, c-fos, c-jun, junB and junD mRNA as well as AP-1 induction paralleled the dose-response for induction of cell killing effects, recombination and chromosomal breakage indicating that increased expression of Fos and Jun is related to the generation of MMS and UV-induced genetic changes."( Induction of c-fos, c-jun, junB and junD mRNA and AP-1 by alkylating mutagens in cells deficient and proficient for the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) and its relationship to cell death, mutation induction and chromosomal
Dosch, J; Kaina, B, 1996
)
0.29
" The lacI mutant frequencies were significantly elevated in transgenic mice dosed with ENU at 150 mg/kg (2-fold increase above control) and iPMS at 200 mg/kg (3-fold increase above control) but not in those receiving MMS at 40 mg/kg."( Evaluation of spontaneous and chemical-induced lacI mutations in germ cells from lambda/lacI transgenic mice.
Carr, GJ; Putman, DL; Ritter, AP; Young, RR, 1997
)
0.3
" The critical steps of the assay, however, seem to be dosing and sampling time."( Detection of the two germ cell mutagens ENU and iPMS using the LacZ/transgenic mouse mutation assay.
Liegibel, UM; Schmezer, P, 1997
)
0.3
" But since it is obvious from dose-response curves where the inflection point/threshold lies, it appears that the model might be picking up some irregularities (possibly due to experimental variability in the dose-response curve at concentrations greater than the threshold)."( Indication for thresholds of chromosome non-disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human lymphocytes.
Elhajouji, A; Kirsch-Volders, M; Tibaldi, F, 1997
)
0.3
" This flat dose-response relationship is primarily the result of efficient repair of EO-induced DNA adducts in the fertilized egg, as was evident from the up to 40-fold or 240-fold increased mutant frequencies above NER- or NER+ background levels, respectively, in crosses with NER- females."( Genotoxic effects of inhaled ethylene oxide, propylene oxide and butylene oxide on germ cells: sensitivity of genetic endpoints in relation to dose and repair status.
Nivard, MJ; Vogel, EW, 1998
)
0.3
" After 9-12 h of incubation a dose-response increase in the levels of ATP was readily detected."( Development of a new bioluminescent mutagenicity assay based on the Ames test.
Alvarez, JF; de la Peña, E; González-Coloma, A; Guadaño, A, 1999
)
0.3
" Their effects on cellular DNMT1 are time and dosage dependent but independent of cell type."( Selective depletion of human DNA-methyltransferase DNMT1 proteins by sulfonate-derived methylating agents.
Chuang, LS; Li, BF; Oh, HK; Tan, EH, 2002
)
0.31
"Our results show that the survival frequency is strongly influenced by MMS dosage and exposure time."( Chemoprotection profiles of sodium thiosulfate on methyl methanesulfonate-induced mutagenesis of bacteriophage T4.
Khan, AU; Lal, SK; Malik, A, 2002
)
0.57
" A dosage suppressor screen identified the budding yeast co-chaperone protein Mge1p as a high copy suppressor of the orc2-1-specific lethal effects of adozelesin, a DNA-alkylating drug."( Activation of budding yeast replication origins and suppression of lethal DNA damage effects on origin function by ectopic expression of the co-chaperone protein Mge1.
Burhans, WC; Feng, L; Trabold, PA; Weinberger, M, 2005
)
0.33
" All three chemicals reproducibly generated sublinear (upward convex) dose-response relationships."( Different types of combination effects for the induction of micronuclei in mouse lymphoma cells by binary mixtures of the genotoxic agents MMS, MNU, and genistein.
Lutz, RW; Lutz, WK; Stopper, H; Tiedge, O, 2005
)
0.33
" For xenobiotics that generate adducts without background, the difference is even more pronounced because the dose-response curve starts at zero and the limit of detection of an increase is not affected by background variation."( Biological significance of DNA adducts investigated by simultaneous analysis of different endpoints of genotoxicity in L5178Y mouse lymphoma cells treated with methyl methanesulfonate.
Brink, A; Lutz, WK; Schulz, B; Stopper, H, 2007
)
0.54
" After optimization of incubation and pipetting conditions in the automated test, dose-response curves of various chemicals and environmental samples were assessed."( Completely automated short-term genotoxicity testing for the assessment of chemicals and characterisation of contaminated soils and waste waters.
Brinkmann, C; Eisentraeger, A, 2008
)
0.35
" Dose-response relationships and DLI-values are recorded and compared."( Completely automated short-term genotoxicity testing for the assessment of chemicals and characterisation of contaminated soils and waste waters.
Brinkmann, C; Eisentraeger, A, 2008
)
0.35
"The alkylating agents methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) have non-linear dose-response curves, with a no-observed effect level (NOEL) and a lowest observed effect level (LOEL) for both gross chromosomal damage and mutagenicity."( No-observed effect levels are associated with up-regulation of MGMT following MMS exposure.
Brüsehafer, K; Doak, SH; Dudley, E; Jenkins, GJ; Johnson, G; Newton, RP; Quick, E, 2008
)
0.35
" A dosage up to 10 microg/ml of AN was devoid of mutagenic activity."( Effect of annatto on micronuclei induction by direct and indirect mutagens in HepG2 cells.
Angeli, JP; Antunes, LM; Barcelos, GR; Mantovani, MS; Rocha, BA; Serpeloni, JM, 2009
)
0.35
" Apart from the MMS exposure to sea stars (which showed 100% mortality at higher concentrations after 5d exposure), clear dose-response relationships were observed for both genotoxicity endpoints in each species."( Linking genotoxic responses with cytotoxic and behavioural or physiological consequences: differential sensitivity of echinoderms (Asterias rubens) and marine molluscs (Mytilus edulis).
Brown, RJ; Canty, MN; Hutchinson, TH; Jha, AN; Jones, MB, 2009
)
0.35
"The dose-response relationships for in vitro mutagenicity induced by methylmethanesulfonate (MMS) or methylnitrosourea (MNU) in L5178Y mouse lymphoma (ML) cells were examined."( Dose-response and operational thresholds/NOAELs for in vitro mutagenic effects from DNA-reactive mutagens, MMS and MNU.
Bartels, MJ; Bhaskar Gollapudi, B; Fontaine, DD; McFadden, LG; Pottenger, LH; Schisler, MR; Zhang, F, 2009
)
0.35
" Results showed a clear dose-response relationship for all tissues, a low variability and a high sensitivity of the response, demonstrating the effectiveness of the Comet assay to detect genotoxic insult in amphipods."( Genotoxicity assessment in the amphipod Gammarus fossarum by use of the alkaline Comet assay.
Bony, S; Devaux, A; Geffard, O; Lacaze, E, 2010
)
0.36
"As part of a project to develop high throughput versions of the comet assay (single cell gel electrophoresis), with a consequent need for more efficient scoring, we have compared the performance of visual scoring, automated and semi-automated image analysis when assessing comets in the same set of gels from dose-response experiments with typical DNA-damaging agents."( The influence of scoring method on variability in results obtained with the comet assay.
Azqueta, A; Brunborg, G; Collins, A; Gutzkow, KB; Meier, S; Priestley, C; Sallette, J; Soussaline, F, 2011
)
0.37
" Moreover, this class of compounds possesses a generally favorable in vitro ADME profile, along with good exposure levels in plasma and brain following intraperitoneal dosing (30 mg/kg body weight) in mice."( Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.
Dorjsuren, D; Jadhav, A; Maloney, DJ; Rai, G; Simeonov, A; Vyjayanti, VN; Wilson, DM, 2012
)
0.38
" montana concentration led to a proportional increase in the reduction of genotoxicity induced by MMS, indicating a dose-response relationship."( Antigenotoxicity of Roupala montana extract in the mouse micronucleus and comet assays.
Acésio, NO; Cunha, NL; Francielli de Oliveira, P; Januário, AH; Leandro, LF; Tavares, DC; Uchôa, CJ, 2014
)
0.4
"Mutagenic and clastogenic effects of some DNA damaging agents such as methyl methanesulfonate (MMS) and ethyl methanesulfonate (EMS) have been demonstrated to exhibit a nonlinear or even "thresholded" dose-response in vitro and in vivo."( Quantitative assessment of the dose-response of alkylating agents in DNA repair proficient and deficient ames tester strains.
Guérard, M; Tang, L; Zeller, A, 2014
)
0.64
" In-medium dosing with MMS produced a LOGEL of 20 µg/ml, which was very similar to the topical LOGEL when considering the total mass of MMS added."( Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses.
Chapman, KE; Doak, SH; Jenkins, GJ; Pfuhler, S; Thomas, AD; Wills, JW, 2014
)
0.4
" As a continuation of our earlier report that analyzed ethyl methanesulfonate (EMS) and methyl methanesulfonate (MMS) dose-response data (Gollapudi et al."( Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment.
Abraham, L; Bodger, OG; Dearfield, KL; Gollapudi, BB; Heflich, RH; Hixon, JG; Johnson, GE; Lovell, DP; MacGregor, JT; Pottenger, LH; Soeteman-Hernández, LG; Tanir, JY; Thompson, CM; Thybaud, V; van Benthem, J; White, PA; Zeiger, E, 2014
)
0.62
"The effective dose (ED) is the pharmaceutical dosage required to produce a therapeutic response in a fixed proportion of the patients."( A random set approach to confidence regions with applications to the effective dose with combinations of agents.
Jankowski, H; Ji, X; Stanberry, L, 2014
)
0.4
" Selection of an appropriate in vitro dosing regime is imperative in determining the genotoxic effects of test chemicals."( Acute dosing and p53-deficiency promote cellular sensitivity to DNA methylating agents.
Chapman, KE; Doak, SH; Jenkins, GJ, 2015
)
0.42
"The nature of the dose-response relationship for various in vivo endpoints of exposure and effect were investigated using the alkylating agents, methyl methanesulfonate (MMS) and methylnitrosourea (MNU)."( Dose-Response for Multiple Biomarkers of Exposure and Genotoxic Effect Following Repeated Treatment of Rats with the Alkylating Agents, MMS and MNU.
Bartels, MJ; Gollapudi, BB; Ji, Z; LeBaron, MJ; Pottenger, LH; Schisler, MR; Zhang, F, 2016
)
0.63
" In the MMS treated groups liver and stomach showed significantly elevated DNA damage at each dose level and a significant dose-response relationship."( Evaluation of methyl methanesulfonate, 2,6-diaminotoluene and 5-fluorouracil: Part of the Japanese center for the validation of alternative methods (JaCVAM) international validation study of the in vivo rat alkaline comet assay.
Junker-Walker, U; Martus, HJ; Plappert-Helbig, U, 2015
)
0.78
"Assessing the shape of dose-response curves for DNA-damage in cellular systems and for the consequences of DNA damage in intact animals remains a controversial topic."( Approaches for characterizing threshold dose-response relationships for DNA-damage pathways involved in carcinogenicity in vivo and micronuclei formation in vitro.
Andersen, ME; Clewell, RA, 2016
)
0.43
" It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg."( Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Berry, P; Campo, B; Cao, J; Ciaravino, V; Easom, EE; Erve, JCL; Freund, YR; Gamo, FJ; Guo, D; Jacobs, RT; Plattner, JJ; Rosenthal, PJ; Sanz, LM; Zhang, YK, 2017
)
0.46
" Consistently, the reduced H4 gene dosage was associated with increased HR frequency and elevated resistance to MMS."( Histone H4 dosage modulates DNA damage response in the pathogenic yeast Candida glabrata via homologous recombination pathway.
Kaur, R; Kumar, K; Moirangthem, R, 2020
)
0.56
" However, little is known about adequate RJ dosing and its effects on genetic material."( Royal jelly reduce DNA damage induced by alkylating agent in mice.
Andrade, VM; Beretta, ÂCDL; Dagostin, LS; Damiani, AP; Longaretti, LM; Magenis, ML; Monteiro, IO; Sarter, RJ,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
genotoxinA role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methanesulfonate esterAn organosulfonic ester resulting from the formal condensation of methanesulfonic acid with the hydroxy group of an alcohol, phenol, heteroarenol, or enol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Integrated breast cancer pathway9818

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency19.95260.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.33670.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency50.84130.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.21260.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.19500.000229.305416,493.5996AID743075
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00140.023723.228263.5986AID743223
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency28.33670.000323.4451159.6830AID743066
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency15.84890.65619.452025.1189AID927
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency42.16320.000627.21521,122.0200AID651741
Cellular tumor antigen p53Homo sapiens (human)Potency12.47120.002319.595674.0614AID651631
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency15.84891.584913.004325.1189AID927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (161)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (47)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID54274Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 100 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID1853140Effect on DNA damage repair in Caulobacter vibrioides lacking uvrA expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1761350Genotoxicity in Salmonella typhimurium TA1535 assessed as number of revertant by Ames spot test relative to solvent control
AID614185Induction of DNA methylation at calf thymus DNA assessed as 3-MeA adduct level per mol of DNA at 5000 uM after 24 hrs by reverse phase HPLC in presence of 100 uM netropsin2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
DNA site-specific N3-adenine methylation targeted to estrogen receptor-positive cells.
AID514319Suppression of HEM1 gene in Saccharomyces cerevisiae harboring cdc28-as transfected with 2 uM expression vector TEplac195 at 0.015% using multicopy pool construction by TAG microarray2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID1780977Genotoxicity in human TK6 cells assessed as decrease in cell proliferation at 20 uM incubated for 3 hrs by comet assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1761353Genotoxicity in Salmonella typhimurium TA100 assessed as number of revertant by Ames spot test relative to solvent control
AID614184Induction of DNA methylation at calf thymus DNA assessed as 3-MeA adduct level per mol of DNA at 5000 uM after 24 hrs by reverse phase HPLC2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
DNA site-specific N3-adenine methylation targeted to estrogen receptor-positive cells.
AID614191Induction of DNA methylation at calf thymus DNA assessed as 7-MeG adduct level per mol of DNA at 5000 uM after 24 hrs by reverse phase HPLC in presence of 100 uM netropsin2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
DNA site-specific N3-adenine methylation targeted to estrogen receptor-positive cells.
AID1221798Genotoxicity in HEK293 cells expressing UGT1A3 assessed as DNA strand breaks at 0.1 mM after 24 hrs by comet assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID95056Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 10ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID614190Induction of DNA methylation at calf thymus DNA assessed as 7-MeG adduct level per mol of DNA at 5000 uM after 24 hrs by reverse phase HPLC2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
DNA site-specific N3-adenine methylation targeted to estrogen receptor-positive cells.
AID95055Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 100ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID1770465Genotoxicity in human HepG2 cells assessed as induction of DNA strand breaks at 1 mM measured after 2 to 72 hrs by alkali comet assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.
AID1809264Binding affinity to calf thymus DNA assessed as 3-MeA adduct formation at 5000 uM after 24 hrs in presence of netropsin by RP-HPLC analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
AID134111Mean life extension in mice bearing Trypanosoma rhodesiense, after ip administration at a dose of 0.2 mmol/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Methylating agents as trypanocides.
AID1809259Binding affinity to calf thymus DNA assessed as 3-MeA adduct formation at 5000 uM after 24 hrs in presence of netropsin by RP-HPLC analysis relative to control2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
AID672553Inhibition of APE1 in human HeLa cells assessed as accumulation of genomic AP sites at 275 uM after 24 hrs by aldehyde reactive probe-based assay relative to control2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.
AID1770466Genotoxicity in human HepG2 cells assessed as induction of alkali labile sites at 1 mM measured after 2 to 72 hrs by alkali comet assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.
AID514320Suppression of HEM1 gene in Saccharomyces cerevisiae harboring cdc28-as at 0.002% using deletion pool construction by TAG microarray2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID1809256Binding affinity to calf thymus DNA assessed as 3-MeA adduct formation at 5000 uM after 24 hrs by RP-HPLC analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
AID614205Induction of DNA methylation at calf thymus DNA assessed as 3-MeA adduct level per mol of DNA after 24 hrs by reverse phase HPLC2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
DNA site-specific N3-adenine methylation targeted to estrogen receptor-positive cells.
AID614198Cytotoxicity against human MCF7 cells after 16 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
DNA site-specific N3-adenine methylation targeted to estrogen receptor-positive cells.
AID54279Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 50 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID54275Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 10 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID680878TP_TRANSPORTER: RT-PCR in vitro, liver epithelial cells1998Biochemical and biophysical research communications, Apr-07, Volume: 245, Issue:1
Induction of multidrug resistance gene expression in rat liver cells in response to acute treatment by the DNA-damaging agent methyl methanesulfonate.
AID1809257Binding affinity to calf thymus DNA assessed as 7-MeG adduct formation at 5000 uM after 24 hrs by RP-HPLC analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
AID1809266Binding affinity to calf thymus DNA assessed as 7-MeG adduct formation at 5000 uM after 24 hrs in presence of netropsin by RP-HPLC analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
AID513198Inhibition of p53-mediated transactivation in human MCF7 cells in presence of 35 ug/ml of methylmethane sulphonate after 24 hrs by beta-galactosidase reporter gene assay2006Nature chemical biology, Sep, Volume: 2, Issue:9
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.
AID1809258Binding affinity to calf thymus DNA assessed as 3-MeA adduct formation at 5000 uM after 24 hrs by RP-HPLC analysis relative to control2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
AID95060Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 50ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID1457306Genotoxicity in Escherichia coli WP2uvrA assessed as number of revertants per plate at 1000 ug/plate in absence of rat liver S9 fraction by Ames test (Rvb = 45 +/- 9 No_unit)2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,404)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990745 (30.99)18.7374
1990's577 (24.00)18.2507
2000's639 (26.58)29.6817
2010's384 (15.97)24.3611
2020's59 (2.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.72 (24.57)
Research Supply Index7.81 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index66.10 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews29 (1.18%)6.00%
Case Studies1 (0.04%)4.05%
Observational0 (0.00%)0.25%
Other2,431 (98.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies [NCT01760655]Phase 262 participants (Actual)Interventional2012-12-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]